Promising AR-targeted strategies in clinical trials have been reported in several non-prostatic cancers, such as hepatocellular carcinoma, breast cancer, bladder cancer, and ovarian cancer37,50–53. This evidence concerns the gene AR and hepatocellular carcinoma.